ASCO 2014: Lilly's Cyramza REVELs in slight lung cancer OS advance
This article was originally published in Scrip
Executive Summary
Eli Lilly's novel anti-angiogenesis monoclonal antibody product ramucirumab (Cyramza) extended life in lung cancer patients by an average of six weeks in the Phase III REVEL study, the full data presented at ASCO this weekend show. While not huge, the difference is enough to lead analysts to believe that the drug will be able to expand its indication into this additional market –Lilly is expected to file later this year.